[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632221":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":25,"studyPopulation":26,"armGroups":21,"interventions":27,"overallOfficials":21,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":21,"id":57,"slug":21,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":21,"studyType":69,"phases":21,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":77,"whyStopped":21,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"First Affiliated Hospital of Zhejiang University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Diagnostic efficacy","Sensitivity, specificity, positive and negative predictive value of 18F-OC PET\u002FCT and PET\u002FMR Imaging in neuroendocrine neoplasms","through study completion, an average of 1.5 year",[14,18],{"measure":15,"description":16,"timeFrame":17},"Standard uptake value （SUV）of tumor","This measure evaluates the association between baseline 18F-FAPI PET parameters (e.g., SUVmax, SUVmean).","through study completion, 3-4 years",{"measure":19,"description":20,"timeFrame":17},"Prognostic Value of Baseline 18F-FAPI PET for Progression-Free Survival (PFS) in High-Risk Patients","PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model.（PFS in months）",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","PROSPECTIVE","Evaluation of the diagnostic and staging efficacy of 18F-FAPI PET\u002FCT combined with multiparametric MRI This study aims to evaluate the sensitivity, specificity, and accuracy of 18F-FAPI PET\u002FCT combined with multiparametric MRI in gastric cancer patients, providing a basis for clinical application. By performing 18F-FAPI PET\u002FCT and multiparametric MRI imaging on gastric cancer patients, relevant data were collected and analyzed to assess their performance in early diagnosis, staging, and recurrence monitoring. The goal is to provide a scientific basis for clinical physicians in the diagnosis, precise staging, and treatment decision-making of gastric cancer.\n\n2.1.2 Comparative Study of 18F-FAPI PET\u002FCT and Contrast-Enhanced MRI A comparative study of 18F-FAPI PET\u002FCT and contrast-enhanced MRI in gastric cancer patients to evaluate the differences in tumor detection sensitivity, specificity, and accuracy among various imaging modalities. The study aims to clarify their advantages in clinical applications for gastric cancer. The research will focus on analyzing the differences in tumor size, location, metastasis, and pathological characteristics detected by each imaging technique, and explore the potential of 18F-FAPI PET\u002FCT combined with multiparametric MRI in improving the diagnostic accuracy and early detection of gastric cancer.\n\n2.1.3 Analysis of diagnostic differences in gastric cancer subgroups using 18F-FAP PET\u002FCT combined with multiparametric MRI Subgroup analysis was performed based on pathological type, stage, and molecular subtype, stratified by disease pathological type, stage (early\u002Fprogressive\u002Fadvanced), and molecular subtype, to evaluate the differences in sensitivity and specificity of 18F-FAPI PET\u002FCT combined with multiparameter MRI across different patient populations. This study will help identify which specific types of gastric cancer patients are more likely to benefit from 18F-FAPI PET\u002FCT, thereby providing a basis for the development of individualized treatment plans.\n\n2.1.4 Evaluation of Multimodal Imaging Combinations in Predicting Gastric Cancer Prognosis Based on TNM staging and PERCIST criteria, this study evaluates the post-treatment reassessment, efficacy prediction, and prognostic assessment (AUC comparison of PFS\u002FOS) of 18F-FAPI PET\u002FCT combined with multiparametric MRI in gastric cancer. The research aims to analyze the multimodal imaging combination's monitoring capability for tumor response post-treatment and its value in prognostic evaluation, providing clinicians with a more precise tool for therapeutic outcome assessment. It tracks the time from diagnosis to specific events (e.g., CR, PR, SD, PD, recurrence, death) in gastric cancer patients to identify influencing factors. Survival rates over time are plotted using Kaplan-Meier curves to visually compare survival differences across groups. Additionally, Cox proportional hazards model-based multivariate regression quantifies the contribution of factors such as age and pathological stage to survival risk, aiding clinical decision-making.","The purpose of this study was to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET\u002FCT combined with multiparameter MRI in gastric cancer.\n\nPrimary endpoint: Diagnostic efficacy of 18F-FAPI PET\u002FCT combined with multiparametric MRI in gastric cancer patients (sensitivity, specificity, accuracy) secondary end points:\n\n* To compare the diagnostic performance differences between 18F-FAPI PET\u002FCT and contrast-enhanced MRI in the clinical application of gastric cancer; ② Analysis of diagnostic differences in the subgroup (pathological, genetic, etc.) of patients using 18F-FAPI PET\u002FCT combined with multiparameter MRI; ③ Evaluation of 18F-FAPI PET\u002FCT combined with multiparameter MRI in predicting the prognosis of gastric cancer.",[28],{"type":29,"name":30,"description":31,"armGroupLabels":21,"otherNames":21},"DIAGNOSTIC_TEST","patients with suspected or confirmed gastric cancer who have undergone 18F-FAPI PET\u002FCT and MRI (non-contrast + contrast-enhanced scans)","A comparative study of 18F-FAPI PET\u002FCT and contrast-enhanced MRI in gastric cancer patients to evaluate the differences in tumor detection sensitivity, specificity, and accuracy among various imaging modalities. The study aims to clarify their advantages in clinical applications for gastric cancer. The research will focus on analyzing the differences in tumor size, location, metastasis, and pathological characteristics detected by each imaging technique, and explore the potential of 18F-FAPI PET\u002FCT combined with multiparametric MRI in improving the diagnostic accuracy and early detection of gastric cancer.",[33],{"name":34,"role":35,"phone":36,"phoneExt":21,"email":37},"Donghe Chen","CONTACT","0571-87236432","chendonghe@zju.edu.cn",[39],{"facility":40,"status":21,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Pet \u002FCt\u002FMri","Hangzhou","Zhejiang","310003","China","CN",{"type":47,"coordinates":48},"Point",[49,50],120.16142,30.29365,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":36,"phoneExt":21,"email":37},"Dongehe Chen",{"type":56,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100632221",false,"NCT07510867","18F-FAPI PET\u002FCT and MRI in Gastric Cancer","A Prospective Clinical Study on the Application of 18F-FAPI PET Imaging Combined With Multi-parameter MRI in the Diagnosis of Gastric Cancer","Inclusion Criteria:\n\n1. Patients suspected or diagnosed with gastric cancer\n2. 18F-FAPI PET\u002FCT has been performed\n3. Gastric MRI with both non-contrast and contrast-enhanced scans performed\n\nExclusion Criteria:\n\n1. Concurrent presence of other active malignant tumors or a history of other malignant tumors within the past 5 years;\n2. Severe uncontrollable diseases or active infections;\n3. Ineligible participants who cannot provide informed consent for the study;\n4. Patients with suboptimal image quality in 18F-FAPI PET\u002FCT\n5. Patients with suboptimal MRI image quality enhancement","ALL","20 Years","80 Years",{"count":67,"type":68},230,"ESTIMATED","OBSERVATIONAL","The purpose of this study was to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET\u002FCT combined with multiparameter MRI in gastric cancer.",[72],"Gastric Cancer",[74,75,76],"FAPI","PET","MRI","NOT_YET_RECRUITING","2026-03-31",{"date":80,"type":81},"2026-04-06","ACTUAL",{"date":83,"type":68},"2026-05-01",{"date":85,"type":68},"2028-05-31",{"name":5,"class":6},1]